Serum Human Epididymis Protein 4 and Pulmonary Function Before and After Quality Improvement Protocol in Children with Cystic Fibrosis

What this Trial Is About

Researchers are evaluating a quality improvement plan to increase lung function, measured by forced expiratory volume in 1 second (FEV1), in children with cystic fibrosis who have impaired lung function. The study also aims to measure levels of serum human epididymis protein 4 (HE4) before and after improvements in lung function. This observational study involves 35 children aged 6 to 18 years who have been diagnosed with cystic fibrosis with specific lung function criteria. All participants will be followed in a specialized cystic fibrosis clinic established under the quality improvement plan. This clinic is managed by a multidisciplinary team including pediatric lung, nutrition, gastroenterology, chest physiotherapy, and endocrinology specialists. The team will create and adjust individualized treatment plans and care algorithms every three months, using quality improvement tools such as fishbone diagrams and Plan-Do-Study-Act cycles to address areas needing improvement. Participants will have pulmonary function tests at the beginning of the study, then at six months, and finally at one year. The study will monitor changes in lung function and serum HE4 levels over 12 months. The specialized team will track progress and make ongoing adjustments to care to better support each child’s health. The total participation time is one year with regular follow-up visits.

Epididymis Protein 4 and Pulmonary Function With Quality Improvement Protocol Among Cystic Fibrosis Patients